By Ed Frankl 
 

Sanofi said Tuesday that it recorded positive interim results from an early study into its first mRNA-based Covid-19 vaccine candidate.

The Phase 1/2 study showed neutralizing antibody in 91% to 100% of study participants two weeks after a second injection, the French pharmaceutical company said.

No safety concerns were observed and side effects were comparable to that of other messenger RNA, or mRNA, Covid-19 vaccines, Sanofi added.

Further data from the study will presented at a later date, the company said.

"Today, we have a promising mRNA platform, which we're taking to the next level in development, including moving to modified mRNA, and against other diseases, including flu," said Jean-Francois Toussaint, global head of research and development, Sanofi Pasteur.

The company said it is continuing to develop its separate protein candidate vaccine in partnership with GlaxoSmithKline PLC, which is in a Phase 3 study.

 

Write to Ed Frankl at edward.frankl@dowjones.com

 

(END) Dow Jones Newswires

September 28, 2021 02:33 ET (06:33 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.
Sanofi (NASDAQ:SNY)
Historical Stock Chart
From Sep 2021 to Oct 2021 Click Here for more Sanofi Charts.
Sanofi (NASDAQ:SNY)
Historical Stock Chart
From Oct 2020 to Oct 2021 Click Here for more Sanofi Charts.